EA201400164A1 - Скрининговое исследование ингибиторов nik на клеточной основе - Google Patents

Скрининговое исследование ингибиторов nik на клеточной основе

Info

Publication number
EA201400164A1
EA201400164A1 EA201400164A EA201400164A EA201400164A1 EA 201400164 A1 EA201400164 A1 EA 201400164A1 EA 201400164 A EA201400164 A EA 201400164A EA 201400164 A EA201400164 A EA 201400164A EA 201400164 A1 EA201400164 A1 EA 201400164A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cell based
nik
screening study
granules
present
Prior art date
Application number
EA201400164A
Other languages
English (en)
Inventor
Роб Хофт-Ван-Хёйсдёйнен
Шераз Гуль
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201400164A1 publication Critical patent/EA201400164A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение касается скринингового исследования и распознавания ингибиторов белка NIK на клеточной основе. Способ согласно настоящему изобретению позволяет распознавать соединения, ингибирующие активность NIK, связанную с фосфорилированием IKK1. Анализ сочетает применение трансфицированных человеческих эмбриональных клеток почек (HEK) с нерадиоактивным, гомогенным анализом близости с применением "акцепторных" гранул и "донорных" гранул.
EA201400164A 2011-07-27 2012-07-26 Скрининговое исследование ингибиторов nik на клеточной основе EA201400164A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11175584A EP2551670A1 (en) 2011-07-27 2011-07-27 NIK inhibitors cell-based assay
US201161548856P 2011-10-19 2011-10-19
PCT/EP2012/064718 WO2013014244A1 (en) 2011-07-27 2012-07-26 Nik inhibitors cell-based screening assay

Publications (1)

Publication Number Publication Date
EA201400164A1 true EA201400164A1 (ru) 2014-07-30

Family

ID=44992518

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400164A EA201400164A1 (ru) 2011-07-27 2012-07-26 Скрининговое исследование ингибиторов nik на клеточной основе

Country Status (12)

Country Link
US (1) US20140234870A1 (ru)
EP (2) EP2551670A1 (ru)
JP (1) JP2014521326A (ru)
KR (1) KR20140048307A (ru)
CN (1) CN103703369A (ru)
AU (1) AU2012288789A1 (ru)
BR (1) BR112014001514A2 (ru)
CA (1) CA2843124A1 (ru)
EA (1) EA201400164A1 (ru)
IL (1) IL230448A0 (ru)
MX (1) MX2014001064A (ru)
WO (1) WO2013014244A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107557430A (zh) * 2017-10-20 2018-01-09 郑州大学 高通量筛选alkbh5小分子抑制剂的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10229762A1 (de) 2002-07-03 2004-01-22 Aventis Pharma Deutschland Gmbh Pyrazoloisoquinolinenderivaten zur Inhibierung von NFkappaB-induzierende Kinase
CN1791411A (zh) * 2003-03-28 2006-06-21 特里根有限公司 NF－kB的活化特异性抑制剂和治疗心血管疾病中的炎性过程的方法
US7279286B2 (en) * 2003-09-11 2007-10-09 Sanofi-Aventis Deutschland Gmbh High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity
EP1514944A1 (en) * 2003-09-11 2005-03-16 Aventis Pharma Deutschland GmbH High-throughput-Assay with high sensitivity for measuring of the activity of beta-adrenergic receptor kinase and for determining the impact of test substances on such activity
IL173104A0 (en) * 2006-01-12 2006-06-11 Yeda Res & Dev Siva and ubiquintination
EP2315751A1 (en) 2008-06-26 2011-05-04 Amgen Inc. Alkynyl alcohols as kinase inhibitors
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity

Also Published As

Publication number Publication date
KR20140048307A (ko) 2014-04-23
EP2551670A1 (en) 2013-01-30
WO2013014244A8 (en) 2013-03-21
AU2012288789A1 (en) 2014-03-13
JP2014521326A (ja) 2014-08-28
CN103703369A (zh) 2014-04-02
WO2013014244A1 (en) 2013-01-31
CA2843124A1 (en) 2013-01-31
IL230448A0 (en) 2014-03-31
MX2014001064A (es) 2014-03-27
EP2737314A1 (en) 2014-06-04
BR112014001514A2 (pt) 2019-09-24
US20140234870A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
EA201792420A1 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
BR112017027498A2 (pt) anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença.
NI201500103A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos.
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
EA202192126A2 (ru) Способы сбора культур клеток млекопитающих
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201591467A1 (ru) Анти-lag-3 связывающие белки
BR112012028764A2 (pt) anticor-pos antifgfr2
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
MA38308B1 (fr) Molécules de liaison à l'antigène bispécifiques activant des lymphocytes t
EA201590247A1 (ru) Антитела к siglec-15
EA201591515A1 (ru) Полипептиды il-22, химерные белки il-22 fc и их применение
EA201491574A1 (ru) Применение car, основанных на icos, для усиления противоопухолевой активности и длительного сохранения car
EA201590671A1 (ru) Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
EA201491833A1 (ru) Основанные на клетках перекрестные анализы и их применение
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
EA201491423A1 (ru) Соединения имидазопирролидинонов
EA201491721A1 (ru) Соединения и способы модуляции киназ и показания для их применения
EA201400875A1 (ru) Антитела к cd47 и способы их применения
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
EA201790882A1 (ru) Способы и композиции для терапии рака печени
EA202090805A1 (ru) Клетки для получения рекомбинантной идуронат-2-сульфатазы
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
EA201600354A1 (ru) Антигенсвязывающая молекула, содержащая вариабельную область антитела
EA201890391A1 (ru) Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы